More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

Small molecules dominate recent new drug approvals, but how are they factoring in the recent or potential revenue gains of the top pharma companies? DCAT Value Chain Insights examines the winners and contenders among small-molecule drugs. Small...

Vaccines, historically a commoditized sector, have risen to the top of the industry's watch list as the race for a vaccine against the novel coronavirus is on. What else is on DCAT Value Chain Insights' Top 10 Watch List for Biologics and...

Although a niche area, cell and gene therapies represent an active area of investment by CDMOs/CMOs to build manufacturing capabilities as well as having new CDMOs/CMOs enter this sector. Which companies are making the moves? Building capabilities...

Nine associations, including those representing innovator and generic-drug companies and chemical manufacturers in Europe, have recommended measures to the European Commission and European Union (EU) member states to address supply issues of drugs...

European Union (EU) authorities have issued guidance to pharmaceutical companies and suppliers to provide regulatory flexibility when sourcing reagents, starting materials, intermediates, and APIs for medicines deemed crucial in treating patients...

In the wake of COVID-19, industry groups, including the Pharmaceutical Research and Manufacturers of America and the Association of Accessible Medicines, are raising concerns over reduced availability of international air transportation and...

Johnson & Johnson reported this week that it expects its lead vaccine candidate against the novel coronavirus (COVID-19) to enter clinical trials in September and outlined a manufacturing plan. Sanofi, GSK, Pfizer, Moderna, and CureVac are...

With a cost of $2.6 billion to bring a new drug to market, a slowing of drug-development activities can have a significant cost to both pharmaceutical companies and CDMOs/CMOs. To address impacts of the novel coronavirus (COVID-19) on clinical...

In response to the novel coronavirus and India's reliance on active pharmaceutical ingredient (API) production outside of the country, the Indian government has put forth a $1.3-billion multi-year plan to increase domestic production of key...